Pre-clinical evidence suggests that CD40L or CD40 antibodies can be used to induce DC and macrophage-mediated cytokine release, antigen processing, tumor stroma destruction, and T-cell activation against established malignancies [82]. The gene discussed is CD40LG; the disease is neoplasm.